Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents.
This randomized, double-blind study on 79 patients reported the efficacy of ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents. Comparisons were made with aspirin-dipyridamole-buflomedil and buflomedil-placebo combinations as controls. Global symptoms, sensorimotor disorders and vertigo were improved in all treatment groups, although improvement tended to be more pronounced with ticlopidine-pentoxifylline. None of the groups showed any change in stenosis or vessel wall rigidity although ticlopidine-pentoxifylline reduced flow irregularity. This combination therapy also normalized the direction of flow in the ophthalmic artery in 46.2% of patients with retrograde flow prior to treatment, compared with 30.0% following aspirin-dipyridamole-buflomedil and 28.6% following buflomedil-placebo administration. Significantly fewer cerebrovascular accidents occurred after treatment with ticlopidine-pentoxifylline. In conclusion, ticlopidine-pentoxifylline showed good therapeutic efficacy against atherosclerosis and a preventative effect against new cerebrovascular accidents. This therapy was well tolerated.
Apollonio
A
A
Internal Medicine Department, Tarquinia Hospital, Italy.
Castignani
P
P
Magrini
L
L
Angeletti
R
R
D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use; D011897:Random Allocation; D013805:Theobromine / Q000031:analogs & derivatives*; D013988:Ticlopidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D011759:Pyrrolidines; D014665:Vasodilator Agents; D004176:Dipyridamole; D013805:Theobromine; D013988:Ticlopidine; D001241:Aspirin; D010431:Pentoxifylline; C010651:buflomedil